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The inhibitors of apoptosis (IAP) proteins cIAP1 and cIAP2 have recently emerged as key ubiquitin-E3 ligases regulating innate
immunity and cell survival. Much of our knowledge of these IAPs stems from studies using pharmacological inhibitors of IAPs,
dubbed Smac mimetics (SMs). Although SMs stimulate auto-ubiquitylation and degradation of cIAPs, little is known about the
molecular determinants through which SMs activate the E3 activities of cIAPs. In this study, we ﬁnd that SM-induced rapid
degradation of cIAPs requires binding to tumour necrosis factor (TNF) receptor-associated factor 2 (TRAF2). Moreover, our data
reveal an unexpected difference between cIAP1 and cIAP2. Although SM-induced degradation of cIAP1 does not require cIAP2,
degradationofcIAP2criticallydependsonthepresenceofcIAP1.Inaddition,degradationofcIAP2alsorequirestheabilityofthe
cIAP2 RING ﬁnger to dimerise and to bind to E2s. This has important implications because SM-mediated degradation of cIAP1
causes non-canonical activation of NF-jB, which results in the induction of cIAP2 gene expression. In the absence of cIAP1,
de novo synthesised cIAP2 is resistant to the SM and suppresses TNFa killing. Furthermore, the cIAP2-MALT1 oncogene, which
lacks cIAP2’s RING, is resistant to SM treatment. The identiﬁcation of mechanisms through which cancer cells resist SM
treatment will help to improve combination therapies aimed at enhancing treatment response.
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Advances in our understanding of the molecular mechanisms
through which cancer cells bypass the apoptotic programme
has aided the design of novel, potentially more selective and
effective strategies for cancer treatment. The development of
Smac mimetic (SM) compounds, designed to inhibit members
of the inhibitor of apoptosis protein (IAP) family and to
sensitisecancercellstodeath,representssuchanapproach.
1
SM compounds are a class of small pharmacological
molecules that mimic the amino-terminal IAP-binding motif
(AVPI) of mature Smac (also known as DIABLO), a member
of the loosely deﬁned family of IAP antagonists.
2 These
compounds selectively bind to the Baculoviral IAP Repeat
(BIR)2 and BIR3 domains of numerous IAPs.
3 The mamma-
lian IAPs, XIAP, cIAP1and cIAP2 contain three such domains
in their amino-terminal portion. These IAPs also harbour
additional domains such as the RING-ﬁnger domain that
provides them with Ubiquitin (Ub) ligase (E3) activity,
4 a
Ub-associated domain through which they interact with
ubiquitylated proteins,
5,6 and in the situation of cIAP1 and
cIAP2, a caspase-recruitment domain of unknown function.
Although IAPs are best known for their ability to inhibit
caspases,
7 they also fulﬁl survival-signalling functions inde-
pendent of controlling caspases. In particular, cIAP1 and
cIAP2 modulate Ub-dependent signalling events that regulate
NF-kB. cIAPs are required for stimulus-dependent activation
of the canonical pathway and for constitutive suppression of
the non-canonical NF-kB pathway.
8–15
Under unstimulated conditions, non-canonical NF-kB
signalling is suppressed by cIAP-mediated degradation of
NF-kB-inducing kinase (NIK). cIAP-mediated degradation of
NIK also requires tumour necrosis factor (TNF) receptor-
associated factor (TRAF)2 and TRAF3, which function as
adaptor proteins recruiting NIK to cIAPs. Loss of TRAF2,
TRAF3 or cIAPs prevents NIK turnover and results in the
accumulation of NIK protein levels and in the stimulation
of non-canonical NF-kB signalling.
8 In the situation of the
canonical NF-kB pathway, stimulation with TNFa leads to
recruitment of cIAPs through TRAF2 to the plasma mem-
brane-bound TNF receptor 1 (TNF-R1) signalling complex,
dubbed complex-I. After its recruitment, cIAPs promote
ubiquitylation of components of this complex, such as
receptor-interacting protein 1 (RIP1).
16 This in turn stimulates
the recruitment of the kinase complexes TAK1–TAB2–TAB3
and NEMO–IKKa–IKKb and ultimately results in the nuclear
translocation of NF-kB dimers. Recent studies have indicated
that cIAPs are not only required for proper regulation of
NF-kB but also for suppression of cell death during TNFa
signalling.
9,11,12,14,17,18
Although originally designed to inactivate XIAP, SMs are
most effective with cIAP1 and cIAP2. Within minutes of
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www.nature.com/cddexposure, SMs trigger auto-ubiquitylation and proteasomal
degradation of cIAP1 and cIAP2—although cIAP2 is depleted
with slower kinetics in most cases.
9,11,12,14,17,19 This results
in stabilisation of NIK and spontaneous activation of
non-canonical NF-kB. In SM-sensitive cells, this leads to
NF-kB-mediated production of autocrine TNFa, overstimula-
tion of TNF-R1, followed by RIP1-dependent cell death.
Over the last few years, several small pharmacological
inhibitors of these IAPs have been developed that are
currently undergoing clinical trails. Although it is clear that
these compounds stimulate auto-ubiquitylation and degrada-
tion of cIAPs, it remains enigmatic how such SMs promote
activationoftheE3ligaseactivityofthesecIAPs.Inthisstudy,
we show that TRAF2 is required for SM-induced degradation
ofcIAP1andcIAP2.Moreover,ourdatarevealanunexpected
difference between cIAP1 and cIAP2 in their response to
SM treatment.
Results
TRAF2 is required for SM-induced degradation of
cIAP1. Despite the importance of TRAF2 for cIAP
function,
20 little is currently known regarding the contribution
of TRAF2 to SM-induced rapid degradation of cIAPs. Using
biotinylated SMs that bind cIAP1 and cIAP2,
17 we found that
TRAF2 readily co-puriﬁed with cIAP1 and cIAP2, indicating
that SM-bound cIAPs are associated with TRAF2 (Figure 1a).
To examine the requirement of TRAF2 for SM-induced
degradation of cIAP1, we tested three different SMs: the
bivalent compound A (Comp. A)
11 and the monovalent
SMs Comp. C (RF and JS, unpublished observation) and
LBW242.
14 Although all three SMs triggered depletion of
endogenous cIAP1 in WT mouse embryonic ﬁbroblasts
(MEFs) (Figure 1b), TRAF2
 /  MEFs were refractory to rapid
SM-induced degradation of cIAP1. To exclude the possibility
that this effect was due to a genetic drift among different cell
lines, rather than due to the speciﬁc loss of TRAF2, we used
MEFs with loxP sites on either side of the TRAF2 gene
(MEF
loxP T2 loxP) (Figure 1c). After infection with a lentivirus-
expressing Cre recombinase, TRAF2 is removed resulting in
conditionally knocked out TRAF2
cko /  MEFs that are other-
wise genetically identical to the parental MEF
loxP T2 loxP.
When treated with LBW242, TRAF2
cko /  MEFs were
resistant to SM-induced degradation of cIAP1. Under
the same conditions, SMs did induce cIAP1 degradation in
control MEF
loxP T2 loxP that expressed GFP instead of Cre
recombinase (Figure 1c). Taken together, these results
demonstrate that SMs are most effective at degrading cIAP1
when TRAF2 is present.
Next, we tested the requirement of TRAF1 and TRAF3 for
SM-induced degradation of cIAP1. TRAF1 can bind cIAP1
directly, whereas TRAF3 binds cIAPs indirectly through
TRAF2.
8,21–23 Unlike TRAF2, the loss of TRAF1 or TRAF3
did not block SM-induced degradation of cIAP1 (Figure 1d),
although the loss of TRAF3 slightly delayed SM-stimulated
cIAP1 depletion (Figure 1d). Importantly, the inability of the
SM to induce cIAP1 degradation in TRAF2
 /  MEFs was not
due to a failure of cIAP1 to bind to the SM in the absence of
TRAF2(Figure1e).Takentogether,theseresultsindicatethat
TRAF2, but not TRAF1 or TRAF3, is required for SM-induced
cIAP1 degradation.
The loss of TRAF2 causes constitutive activation of the
non-canonical NF-kB pathway.
11,24,25 As NF-kB transcription
factors induce expression of a large number of target genes
the products of which might inﬂuence SM-mediated degrada-
tion of cIAP1, we generated TRAF2
 /  MEFs in which NF-kB-
mediatedinductionoftargetgeneswasblockedbyexpressing
IkB-super repressor (IkB-SR), a non-degradable, dominant
negative form of the NF-kB inhibitor, IkB (Figure 1f and
SupplementaryFigureS1).ItisnoteworthythatIkB-SRblocks
gene induction in response to canonical and non-canonical
NF-kB-signalling (Supplementary Figure S1 and Vince
et al.
11). Although IkB-SR blocked NF-kB-mediated gene
expression, it failed to restore SM-induced cIAP1 degradation
in TRAF2
 /  MEFs (Figure 1g). Moreover, knockdown of NIK
or p100 did not inﬂuence SM-induced degradation of cIAP1
in TRAF2-deﬁcient cells (Supplementary Figure S1). This
indicates that the inability of the SM to trigger cIAP1
degradation in TRAF2
 /  MEFs is not caused by NIK or
upregulation of some putative NF-kB target gene products,
but instead is due to the speciﬁc loss of TRAF2.
SM-induced degradation of cIAP1 requires TRAF2
binding but not TRAF2’s E3 ligase activity. Given that
cIAP1 binds to TRAF2 through BIR1,
21,22 we examined the
role of the BIR1 domain for SM-induced degradation of
cIAP1. To this end, we transiently transfected HEK293T cells
with cIAP1
WT and cIAP1
DBIR1 that lacks the BIR1 domain and
therefore fails to bind to TRAF2 (Figure 2a and Supple-
mentary Figure S2). SM-induced degradation of cIAP1 was
dependent on TRAF2 binding because treatment with
LBW242 failed to efﬁciently deplete cIAP1
DBIR1 while
cIAP1
WT was rapidly degraded (Figure 2b). It is noteworthy
that cIAP1
DBIR1 is partially degraded by the SM compound
under these conditions, although to a lesser extent than wild-
type cIAP1. Most likely, this is due to the overexpression
conditions using HEK293T cells. SM-induced cIAP1
degradation was not rescued in TRAF2
 /  MEFs reconsti-
tuted with TRAF2
DCIM, a TRAF2 mutant that lacks the cIAP1-
interacting motive (CIM, D283–293)
20 (Figure 2c). In
contrast, reconstitution of TRAF2
 /  MEFs with TRAF2
WT
or TRAF2
DRING, which lacks its amino-terminal RING-ﬁnger
domain, rescued SM-induced degradation of cIAP1.
Together with previous data, these results indicate that
apart from a functional RING of cIAP1 and binding of the SM
to the BIR2/3 domains, binding of TRAF2 to cIAP1 is
necessary for SM-induced cIAP1 degradation. Although
TRAF2 carries a RING ﬁnger, this domain is dispensable
for SM-induced degradation of cIAP1, ruling out the
possibility that TRAF2 acts as the E3 for cIAP1.
Next, we addressed whether TRAF2 contributes to SM-
induced degradation by enhancing the E3 ligase activity of
cIAP1. Recombinant cIAP1 possesses intrinsic E3 ligase
activity even in the absence of TRAF2 under in vitro
conditions.
9,12 Accordingly, cIAP1 promotes auto-ubiquityla-
tion in an in vitro assay in a concentration-dependent manner
(Figure 2d). When increasing amounts of TRAF2 were added
to the reaction, TRAF2 did not change cIAP1-mediated auto-
ubiquitylation (Figure 2e), indicating that TRAF2 does not
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conditions.
To address the possibility that TRAF2 recruits ubiquitylated
cIAP1 to the degradation machinery, we examined whether
auto-ubiquitylated cIAP1 accumulates in the absence of
TRAF2. In the absence of TRAF2, we failed to detect any
discernable levels of ubiquitylated cIAP1 (Figure 2f), render-
ing it unlikely that TRAF2 recruits ubiquitylated cIAPs to the
proteasome. Taken together, our data are consistent with a
model in which TRAF2 functions as an essential cofactor for
cIAP1’s E3 activity upon SM treatment because it acts as a
scaffold allowing high local concentration of cIAP1. This might
facilitate dimerisation of cIAP’s RING, which is required
for cIAPs’ E3 activity.
26,27 According to this scenario, cIAP1
RING dimerisation may be hampered in the absence of
TRAF2.
SM-induced degradation of cIAP2 is dependent on
TRAF2 and cIAP1. Next, we tested whether TRAF2
is also required for SM-mediated degradation of cIAP2. As
there are currently no good antibodies available that would
detect mouse cIAP2 at endogenous levels, we generated
WT
i cIAP2 and TRAF2
 / ;i cIAP2 MEFs that carry an inducible
transgene encoding human cIAP2, for which good antibodies
exist. Like for cIAP1, cIAP2 was readily degraded in WT
MEFs (Figure 3a). However, MEFs lacking TRAF2 showed
impaired degradation of cIAP2. Interestingly, when cIAP2
was introduced into cIAP1/2 double-knockout (DKO) MEFs,
LBW242 treatment failed to induce rapid degradation of
cIAP2 (Figures 3a and b), indicating that cIAP2 degradation
critically depends on the presence of cIAP1. In contrast,
degradation of cIAP1 was not dependent on cIAP2, as cIAP1
reconstituted in DKO MEFs was efﬁciently degraded upon
LBW242 treatment (Figure 3c). Importantly, cIAP1 was not
required for cIAP2 to bind to the SM compound, nor did it
affect cIAP2’s ability to bind to TRAF2 (Figure 3d).
Furthermore, SM-mediated degradation of cIAP2 was also
impaired in human cells, in which cIAP1 was knocked down
by RNA interference (RNAi) (Supplementary Figure S3, see
the Materials and Methods section for details). These results
indicate that cIAP2 relies on the E3 activity of cIAP1 for its
degradation upon SM treatment. This observation is
consistent with earlier reports suggesting that cIAP1 targets
cIAP2 for proteasomal degradation.
28,29 Although cIAP2 fails
to promote its own degradation in the absence of cIAP1
under these conditions, cIAP2 is not generally inactive as E3.
In the absence of cIAP1, cIAP2 readily promoted TNF-
induced ubiquitylation of RIP1, degradation of NIK and
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Figure 1 TRAF2 is required for Smac mimetic (SM)-induced cIAP1 degradation. (a and e) Biotinylated SM was used to purify SM-binding proteins from lysates of MDA-
MB-231 (a) and MEFs (e). The presence of co-puriﬁed proteins was established by immunoblotting the eluate with the indicated antibodies. (b–d and g)W T
andTRAF-knockoutMEFs were treatedwith 100nM Comp.A, 100nM Comp.C and 1mM LBW242 for the indicatedtime points (min).The presence of theindicatedproteins
was established by immunoblotting the lysates with the indicated antibodies. Asterisks indicate nonspeciﬁc bands. (f) Secreted luciferase reporter assays using
TRAF2
 / ,i IkB SRMEFs.Cellswereleftuntreatedortreatedwith100ng/mldoxocycline(Dox) toinduceIkB-SR.Themediumwasanalysedforluciferaseactivity24hlater.
Luciferase activity is shown relative to the uninduced condition. The error bar indicates S.D. of triplicate experiments. (g) TRAF2
 / ,i IkB SR MEFs were left uninduced or
induced with Dox and treated with 1mM LBW242 for the indicated time points
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Cell Death and Differentiationsuppression of p100 processing (Figures 3e–g). Therefore,
cIAP2 is fully competent in promoting ubiquitylation of bona
ﬁde substrates. However, in the absence of cIAP1, cIAP2’s
E3 ligase activity does not allow auto-ubiquitylation in
response to SM treatment.
RING dimerisation and E2 binding is required for cIAP2
degradation. Next, we addressed the role of cIAP2’s own
RING ﬁnger for SM-induced, cIAP1-directed degradation of
cIAP2. To this end, we focussed on cIAP2
DRING lacking
the RING ﬁnger, the RING-dimerisation mutant cIAP2
V568E
and the E2-binding mutant cIAP2
L585A/I590A (RF and JS,
unpublished observation). Although LBW242 readily
degraded cIAP2
WT, it was ineffective in degrading
cIAP2
DRING, cIAP2
V568E or cIAP2
L585A/I590A (Figure 4a).
This indicates that RING dimerisation and E2 binding of
cIAP2 is required for SM-induced degradation.
The loss of cIAP2’s RING ﬁnger is frequently found in
cIAP2-MALT1. Reciprocal chromosomal translocation of
cIAP2andtheparacaspaseMALT1geneisthemostprevalent
chromosomal aberration associated with MALT lymphoma
(Figure 4b).
30 cIAP2-MALT1 drives B-cell transformation and
lymphoma progression through constitutive activation of the
canonicalNF-kB signallingpathway.
31 Induceddegradationof
the cIAP2-MALT1 protein by SM compounds could potentially
provide a therapeutic strategy for MALT lymphoma patients
harbouring this translocation. Intriguingly, cIAP2-MALT1 was
completely refractory to SM-induced degradation (Figure 4c).
In addition, when only the cIAP2 portion of cIAP2-MALT1 was
expressed (cIAP2
1 442), SM treatment did not induce degra-
dation, ruling out an inhibitory role of the MALT1 portion
of cIAP2-MALT1 (Figure 4c). Under the same conditions,
full-lengthcIAP2wasreadilydegraded(Figure4aanddatanot
shown). Consistent with the notion that cIAP2-MALT1 is
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 / 
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Cell Death and Differentiationrefractory to SM-mediated degradation, SM treatment did not
diminish the ability of cIAP2-MALT1 to promote NF-kB
activation (Figure 4d). Taken together, these data indicate
that the RING ﬁnger of cIAP2, although unable to promote
auto-ubiquitylation, is nevertheless required for SM-induced
and cIAP1-mediated degradation of cIAP2.
Depletion of cIAP1 results in NF-jB-dependent
induction of cIAP2 gene expression in cancer cells.
The observation that SM-induced degradation of cIAP2
is ineffective in the absence of cIAP1 has important
ramiﬁcations as it predicts that SM treatment will be
unsuccessful under conditions in which cIAP1 is absent
and cIAP2 is expressed to high levels. To investigate the
efﬁciency of SM compounds in cancer cells, we used
HT1080 ﬁbrosarcoma cells (Figure 5a). Treatment with
LBW242 led to efﬁcient degradation of both cIAP1 and
cIAP2 within the hour. However, at 24h, cIAP2 levels
dramatically increased and were signiﬁcantly higher
compared with controls (Figure 5a), whereas cIAP1 levels
remained undetectable. Re-challenging cells with the SM
after the initial treatment did not induce cIAP2 degradation at
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(b) LBW242 also fails to degrade cIAP2 at later time points (24h). (c) DKO
i cIAP1 MEFs that inducibly express cIAP1 were used to assess whether SMs stimulate cIAP1
degradation in the absenceof cIAP2. cIAP1 expressionwas induced with 10nM 4-hydroxy-tamoxifen for 16h, followedby treatment with 1mM LBW242for the indicatedtime
points. (d–f) cIAP2 expression was induced with Dox for 16h after which cells were analysed. (d) Biotinylated SM was used to purify SM-binding proteins from lysates of the
indicated MEFs. Asterisks indicate nonspeciﬁc bands. (e) cIAP2 readily promotes ubiquitylation of RIP1 in complex-I after TNFa stimulation. DKO
i cIAP1 MEFs were left
untreated or treated with Dox to induce cIAP2 expression, and complex-I was puriﬁed using FLAG-tagged TNFa. Co-puriﬁed proteins were analysed by immunoblotting.
(f) Induced expression of cIAP2 results in suppression of p100 cleavage. (g) cIAP1 and cIAP2 are capable of targeting NIK for degradation. NIK was co-transfected with
GFP, cIAP1 or cIAP2 in 293T cells
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Cell Death and Differentiation24h, ruling out the possibility that the compound became
ineffective at later time points (Figure 5a). SM-induced
upregulation of cIAP2 seems to be a common phenomena
as it is also seen in several other cancer cell lines, such as
MDA-MB-231 (breast cancer), A2058 and Me4405
(melanoma) (Figures 5b and c).
Induction of cIAP2 not only occurred after SM treatment but
also in response to RNAi-mediated knockdown of cIAP1
(Figures 5d and e). Moreover, it also induced expression of a
cIAP2-Luciferase (cIAP2-Luc) reporter gene (Figures 5f)
containing NF-kB-binding sites of the cIAP2 promoter
region.
32 Similarly, knockdown of TRAF2 also induced
expression of the cIAP2-Luc reporter. Transcriptional induc-
tion of cIAP2 was dependent on the non-canonical NF-kB
pathway as simultaneous depletion of NIK suppressed
induction of cIAP2 gene expression (Figure 5f). Under the
same conditions, knockdown of RIP1 had no effect. Like
RNAi-mediated depletion of cIAP1, SM-induced degradation
of cIAP1 also caused activation of non-canonical NF-kB
signalling in BE and HT1080 cells (Figures 5g and h, see the
Materials and Methods section for details). LBW242-
mediated induction of cIAP2 expression was clearly NF-kB
dependent as the expression of IkB-SR suppressed cIAP2-
Luc reporter activity (Figure 5i and Supplementary Figure S1)
and cIAP2 protein expression (Figure 5j). In agreement with
the notion that cIAP2 expression is under the transcriptional
control of NF-kB,
33 we observed strong induction of the
cIAP2-Luc reporter and cIAP2 protein expression upon
treatment with TNFa and LIGHT or NIK expression
(Figure 5i, and Supplementary Figures S1 and S4), as well
as LBW242 treatment (Figure 5j). These data are consistent
with previous reports showing that loss of cIAP1 leads to
ectopic activation of the non-canonical NF-kB path-
way,
11,12,14,17 which in turn leads to upregulation of cIAP2.
Interestingly, although the loss of cIAP1 by SM treatment leads
to a modest stabilisation of NIK protein levels in HT1080 WT
cells, levels of NIK are signiﬁcantly higher in SM-treated
HT1080
IkB SR cells that cannot induce cIAP2 (Figure 5j). This
isconsistentwiththenotionthatcIAP2functionsastheE3ligase
for NIK, targeting NIK for degradation even in the absence of
cIAP1. Moreover, these data also suggest that induction of
cIAP2 serves as a negative feedback mechanism that dampens
non-canonical NF-kB signalling through degrading NIK.
SM-induced upregulation of cIAP2 dampens TNFa
killing. As depletion of cIAP1 results in compensatory
upregulation of cIAP2, we tested whether cIAP2 can
modulate the sensitivity to TNFa-induced cell death. First,
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Cell Death and Differentiationwe investigated the ability of cIAP2 to suppress TNFa-
induced cell death independently of cIAP1. Indeed, when
cIAP2 expression was induced in reconstituted cIAP1/2 DKO
MEFs, these cells were completely protected from the
cytotoxic effects of TNFa (Figures 6a and b). Moreover,
although coordinated knockdown of cIAP1 and cIAP2
sensitised BE colon cancer cells to TNFa, expression of an
RNAi-resistant cIAP2 rescue construct provided signiﬁcant
protection from TNFa killing (Figure 6c).
Although several cancer cell lines are sensitive to SM, most
cancer cell lines, such as HT1080 and BE cells, are resistant.
Such ‘SM-resistant cells’ stay alive because they fail to
produce autocrine TNFa. However, when supplied with
exogenous TNFa, these cells also rapidly succumb to TNF-
R1-mediated apoptosis. Consistent with the notion that
induced expression of cIAP2 protects from the lethal effects
of TNFa, we ﬁnd that RNAi-mediated knockdown of cIAP2
(Figure 6d) increased sensitivity to TNFa killing upon SM
treatment (Figure 6e and Supplementary Figure S5). This is
consistent with a previous report demonstrating that cIAP2
provides resistance to SM treatment.
19 Moreover, cIAP1/2
DKO MEFs were signiﬁcantly more sensitive to TNFa than
singly cIAP1
 /  MEFs (Figures 6f and g). Taken together,
these data indicate that the expression of cIAP2 is refractory
to degradation by SM in the absence of cIAP1, and that the
induced expression of cIAP2 can provide protection from the
lethal effects of TNFa.
Discussion
The realisation that members of the IAP family are frequently
deregulated in cancer and contribute to chemoresistance and
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34 has sparked renewed interest in the
development of small pharmacological inhibitors of IAPs.
Consistent with the notion that different types of cancer cells
are addicted to IAPs for their survival, inactivation of IAPs,
particularly when combined with other treatments, results
in the death of many tumour cells.
11,12,17,35–37 However, a key
problem in the treatment of cancer is the identiﬁcation of
tumours that are susceptible to a particular treatment.
Moreover, development of resistance represents a major
challenge in the ﬁght against cancer. Hence, a better
understanding of the mechanisms through which SM com-
pounds exert their activities will be essential for the right
choice of target patients, and to limit the likelihood of
resistance development.
In this study, we have addressed the molecular mechanism
through which SMs exercise their IAP-inhibitory activity.
Surprisingly, we ﬁnd that SM-induced degradation of cIAP1
and cIAP2 is dependent on TRAF2 binding. Although TRAF2
is essential for cIAP degradation, and carries a RING-ﬁnger
domain, it does not function as the E3 ligase for cIAPs. This is
evident because the RING-ﬁnger domain of TRAF2 is
dispensableforSM-induceddegradationofcIAP1.Thisnotion
is also consistent with recent structural studies indicating that
the RING of TRAF2 is inactive because it lacks key residues
required for E2 binding.
38 Moreover, although TRAF2/TRAF5
are required for TNFa-mediated NF-kB activation, their RING
ﬁngers, and hence their activity as E3 ligases, are dispen-
sable.
20Therefore,TRAF2merelyseemstofulﬁla scaffolding
function supporting the E3 ligase activity of cIAPs.
Recent evidence has indicated that SMs stimulate dimer-
isationofthe RING domainsofcIAPs, whichinturn isrequired
to promote discharging of Ub from the nascent E2.
26 There-
fore, TRAF2 is likely to function as a binding platform that
facilitates dimerisation of the RING domains of cIAPs.
Intriguingly, structural and biochemical studies indicate that
a single cIAP1 molecule binds the trimeric TRAF2 coiled-coil
domain.
39,40 As only one IAP molecule binds to each TRAF2
trimer, one is left speculating how cIAP1 RING dimer
formation is actually achieved. One possible scenario is that
in vivo TRAFs form higher-order oligomers.
Although degradation of cIAP1 depends on TRAF2,
degradation of cIAP2 requires both TRAF2 and cIAP1.
In the absence of cIAP1 or TRAF2, cIAP2 is no longer
depleted by SM treatment. Although cIAP2 promotes
ubiquitylation of RIP1 and NIK in the absence of cIAP1
(Figures 3d–f), it seems to be unable to target itself for
degradation. Interestingly, cIAP2’s own RING ﬁnger is
essential for SM-induced degradation of cIAP2. The require-
ment of cIAP2’s own RING ﬁnger suggests a model in which
the RING ﬁnger of cIAP2 heterodimerises with the one of
cIAP1 to promote ubiquitylation of cIAP2.
The observation that SM-induced degradation of cIAP2
requires cIAP1 has signiﬁcant implications as it predicts that
SM treatment will be less effective in cancers that lack cIAP1
and express high levels of cIAP2. Importantly, loss of cIAP1 not
only removes the E3 ligase for cIAP2 but also results in
deregulatedactivationof non-canonical NF-kBsignalling, which
in turn leadstoinduction of cIAP2 gene expression. The NF-kB-
dependent increaseinthe levelsofcIAP2 proteindecreasesthe
sensitivity of cancer cells to SM and TNFa-induced apoptosis.
19
Consistent with the notion that cIAP2 protects from the lethal
effects of TNFa, depletion of cIAP2 renders cancer cells more
susceptible to treatment with TNFa and SM. Similarly, cIAP1/2
DKO MEFs are also signiﬁcantly more sensitive to TNFa than
singly cIAP1
 /  MEFs.
Induced expression of cIAP2 seems to protect cells from
the lethal effects of TNFa by two distinct mechanisms: First,
after TNF-R1 engagement, it promotes the ubiquitylation of
components of complex-I, such as RIP1, thereby limiting the
formation of a secondary, RIP1-dependent death-inducing
complex. Second, cIAP2 also seems to protect cells by
targeting NIK for degradation. This decreases the constitutive
activation of non-canonical NF-kB signalling that drives the
production of autocrine TNFa.
The identiﬁcation of potential mechanisms through which
cancer cells can resist SM treatment will not only help to
choosepatientpopulationsthatwillrespondtotheSMbutalso
device better treatment combinations that boost treatment
sensitivity. As cIAP2 gene induction critically depends on NF-
kB signalling, combined treatments of SM and IKK inhibitors,
which block activation of NF-kB activation, are promising
avenues that are expected to dramatically improve treatment
outcome and patient survival.
Materials and Methods
Reagents, constructs and antibodies. Ac-DEVD-AMC was purchased
from Sigma-Aldrich (St. Louis, MO, USA), and recombinant human and mouse
TNFa were obtained from R&D Systems (Minneapolis, MN, USA) and Enzo Life
Sciences (Farmingdale, NY, USA), respectively. Constructs were generated in
pcDNA3 (Invitrogen, Carlsbad, CA, USA) or pEF6 (Invitrogen) using PCR and
conﬁrmed by DNA sequencing. The episomal pCEP-1400-Luciferase reporter
construct was created by replacing the CMV promoter with a fragment containing
the cIAP2 promoter driving luciferase expression. The cIAP2-Luc insert was taken
from pGL2-1400 that was kindly provided by Lee Tae. siRNA-resistant cIAP2
(pCEP4-based) was generated by introducing silent point mutations that impair
siRNA-mediated knockdown. Sequence information can be obtained on request.
The following antibodies were used: a-actin (Santa Cruz Biotechnology, Santa
Cruz,CA,USA),a-cIAP1,a-cIAP2(EnzoLifeSciences),a-panIAP(R&DSystems),
a-TRAF2(SantaCruzBiotechnologyandCalbiochem,SanDiego,CA,USA),a-NIK
(Cell Signaling, Danvers, MA, USA), a-FLAG (Sigma) and a-p100 (Cell Signaling).
Tissue culture and RNAi. Transfections of HEK293T cells were performed
using Effectene transfection reagent (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. The BE colon cancer cell line and HT1080
IkB SR were
kindly provided by C Marshall (ICR, London) and Olivier Micheau (Dijon, France),
respectively. Single and DKO MEFs were generated as described previously.
11
siRNA duplexes were purchased from Ambion (Austin, TX, USA) and Qiagen. Cells
were transfected with siRNA oligos at 50nM ﬁnal concentration using Hiperfect
(Qiagen) according to the manufacturer’s instructions.
Generation of stable cells by lentiviral infection. For reconstitution of
TRAF2
 /  MEFs, TRAF2
 /  MEFs were ﬁrst infected with pFU-Gal4-VP16-PGK-
hygro lentivirus. Selected stable cells were subsequently infected with lentivirus
containing the relevant pF-5xUAS plasmids (TRAF2
WT and mutants). To generate
cells carrying IkB-SR, i-cIAP2, shcIAP2 or shControl, pTRIPZ-based derivatives
(Open Biosystems, Huntsville, AL, USA) were used. To generate 293-FLPin
shcIAP1/
i cIAP2 cells, 293-TRex-FLPin cells (Invitrogen) were infected using lentivirus with
shcIAP1-pTRIPZ(OpenBiosystems).Astableclonewaschosenandknockdownof
cIAP1wasveriﬁedbyimmunoblotting.Thisclonewassubsequentlytransfectedwith
pcDNA5.1-cIAP2 (i-cIAP2) and stable cells were selected using hygromycin.
Reconstitution (knockdown of cIAP1 and expression of cIAP2) was induced in the
presence of 100ng/ml doxocycline for at least 48h.
In vitro ubiquitylation assay. In vitro ubiquitylation assays were performed
in the ubiquitylation buffer (containing 40mM Tris-HCl pH (7.5), 10mM MgCl2,
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Cell Death and Differentiation0.6mM DTT) in the presence of 2mM ATP, 20mg Ub, 0.5mg human E1, 1mg
UbcH5c and variable amounts of cIAP1 or TRAF2. Reactions were performed at
371C for 1h and stopped by boiling in the sample buffer.
Luciferase assays. The pSL-NFkB-Luc reporter plasmid (Clontech,
Mountainview, CA, USA) was used for the secreted luciferase assay. Twenty-
four hours after transfection, cells were split in two and either left uninduced or
induced with doxocycline (100mg/ml). Twenty-four hours later, the medium was
replaced and cells were left for a further 24h, after which Luciferase secretion was
assayedusingtheReady-To-Glow SecretedReporterSystem(Clontech) according
to the manufacturer’s instructions. The cIAP2-Luciferase assay was performed as
describedpreviously.
41BEstablecellsweregeneratedusingthepCEP4[ 1.4kLuc/
cIAP2-promoter].pCEP4isanepisomalexpressionvectorthatismaintainedatfew
copies per cell (Invitrogen).
Biotinylated SM pull-downs. Cells were lysed using 1% Triton lysis buffer
(10mM Tris (pH7.5), 150mM NaCl, 10% glycerol and 1% Triton) containing 50mM
chloroacetimide.Lysateswereclearedbycentrifugation,splitintwoandincubatedeither
with streptavidin sepharose beads (GE Healthcare, Little Chalfont, UK) only or with
beadspre-boundwith200nMbiotinylatedSM.After1hincubationatroomtemperature,
the supernatant was removed and beads were washed 4 times with the IPPG50 wash
buffer. Co-puriﬁed proteins were eluted by boiling in 2 Laemmli sample buffer.
Real-time RT-PCR. Total RNA was isolated using the RNAase mini kit
(Qiagen) according to the manufacturer’s instructions. cDNA was synthesised
from total RNA using QuantiTech Reverse Transcription (Qiagen) according to the
manufacturer’s instructions. Quantitative real-time RT-PCR reactions were per-
formed using SYBR Green (Eurogentec, Seraing, Belgium). Relative mRNA levels
were calculated after normalisation to GAPDH using the DDCt method.
Celldeathassays. Cell death was analysedby usingtheCell Death Detection
ELISA
PLUS kit (Roche) according to the manufacturer’s instructions. For clonogenic
assays, cells were washed with PBS, and 1–5% of cells were re-plated. Cells were
cultured until the control plates were conﬂuent. Viable cells were ﬁxed in 3.7%
formaldehyde/PBS and stained with 0.5% crystal violet/PBS. For quantiﬁcation,
plates were air dried and decolourised with a destaining solution (containing 0.5%
SDS, 0.5% ethanol, 0.5M TRIS-Cl, pH 7.6) for 1h after which OD 586nm was
measured. For DEVDase assay, cells were lysed in 1% Triton lysis buffer and
cleared by centrifugation. The supernatant was added to the DEVDase assay mix
(20mM DEVD-AMC (Calbiochem), 2mM DTT, 10mM Tris (pH 7.5), 150mM NaCl,
0.1% Triton and 5% glycerol). Reactions were analysed at 380nM excitation and
460nM emission.
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